Holy Stone Healthcare 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CA102N / Holy Stone Healthcare
NCT06039202: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
100
NA
CA102N, Nim-HA cinjugate, TAS-102, Trifluridine/tipiracil, Bevacizumab
Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
02/25
10/25
NCT05274204: Individual Patient Expanded Access to CA102N

Temporarily Not Available
N/A
NA
CA102N, Nim-HA Conjugate
Holy Stone Healthcare Co., Ltd
Advanced or Metastatic Colorectal Cancer (mCRC)
 
 
mesalamine/sodium hyaluronate (IBD98-M) / Holy Stone Healthcare
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CA102N / Holy Stone Healthcare
NCT06039202: Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
100
NA
CA102N, Nim-HA cinjugate, TAS-102, Trifluridine/tipiracil, Bevacizumab
Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
02/25
10/25
NCT05274204: Individual Patient Expanded Access to CA102N

Temporarily Not Available
N/A
NA
CA102N, Nim-HA Conjugate
Holy Stone Healthcare Co., Ltd
Advanced or Metastatic Colorectal Cancer (mCRC)
 
 
mesalamine/sodium hyaluronate (IBD98-M) / Holy Stone Healthcare
No trials found

Download Options